



Article

Anti-Inflammatory Effects, Protection of Gut Barrier Integrity and Stimulation of Phagocytosis of Postbiotic Combination ABB C1

Maria Tintoré ^{1,*} , Jordi Cuñé ¹, Vaclav Vetvicka ^{2,3} and Carlos de Lecea ¹¹ AB Biotek Human Nutrition and Health, 08017 Barcelona, Spain² Department Pathology, University of Louisville, Louisville, KY 40292, USA³ International Society for Glucan Research, 101 00 Prague, Czech Republic

* Correspondence: maria.tintore@abbiotekhealth.com; Tel.: +34-676-384-925

Abstract: This study evaluated the anti-inflammatory effects, the protection of gut barrier integrity, and the stimulation of phagocytosis in peripheral cells of a nutritional supplement based on a synergistic combination of yeast-based ingredients with a unique 1,3/1,6-glucan complex and a consortium of postbiotic *Saccharomyces cerevisiae* rich in selenium and zinc. The anti-inflammatory effect in caco-2 cells in the presence and absence of a pro-inflammatory challenge (tumour necrosis factor alpha [TNF- α]/interferon gamma [IFN- γ]) showed statistically significant reductions in IFN- γ induced protein-10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1) levels vs. controls ($p < 0.001$). Disruption of the gut integrity in the presence or absence of *Escherichia coli* (ETEC H10407) showed transepithelial electrical resistance (TEER) values higher in the ABB C1[®] group after 6 h of testing. Spontaneous build-up of the gut epithelium monolayer over 22 days was also greater in the ABB C1[®] condition vs. a negative control. ABB C1[®] showed a significantly higher capacity to stimulate phagocytosis as compared with controls of algae β -1,3-glucan and yeast β -1,3/1,6 glucan ($p < 0.001$). This study supports the mechanism of action by which ABB C1[®] may improve the immune response and be useful to prevent infection and allergy in clinical practice.

Keywords: *Saccharomyces cerevisiae*; beta-glucans; selenium; zinc; inflammatory processes; gut barrier modulation; COVID-19; allergy; nutritional supplementation



Citation: Tintoré, M.; Cuñé, J.; Vetvicka, V.; de Lecea, C. Anti-Inflammatory Effects, Protection of Gut Barrier Integrity and Stimulation of Phagocytosis of Postbiotic Combination ABB C1. *Nutraceuticals* **2023**, *3*, 109–118. <https://doi.org/10.3390/nutraceuticals3010009>

Academic Editor: Emanuel Vamanu

Received: 1 December 2022

Revised: 24 January 2023

Accepted: 29 January 2023

Published: 2 February 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Pro-inflammatory cytokines, the microbiota and the gut barrier function, and phagocytosis are some important mediators involved in the interplay of innate-adaptive immune responses [1–4] for the elimination and clearance of infectious agents, including viruses and the newly appeared SARS-CoV-2 [5–7]. Chemokines such as interferon (IFN) γ -inducible protein 10 (IP-10) are involved in acute exacerbations of asthma [8] and an increase in inflammation and keratinocyte apoptosis in atopic dermatitis [9]. The monocyte chemoattractant peptide-1 (MCP-1) participates in allergen sensitization [10], and it has been shown that MCP-1 produced by keratinocytes plays a role in the process of mononuclear cell infiltration in occupational allergic contact dermatitis [11]. On the other hand, dysregulation of the intestinal barrier has been associated with chronic immune diseases (e.g., food allergy, inflammatory bowel disease, celiac disease); however, bacterial pathogens and components of innate and adaptive immunity have been identified in the underlying regulation pathways of the gut barrier function [12].

In the current era of the pandemic and of growing antibiotic resistance, a focus of interest has been the use of nutritional supplements with anti-inflammatory and immunomodulatory activity relevant to maintain a strong healthy immune system [13,14]. The search for new natural ingredients easily and widely available without the unwanted side effects of pharmaceutical drugs has widened significantly in recent years. Ideal candidates will be

agents that cannot trigger microbial resistance and that can be safely administered to all ages and types of populations, both immunocompromised or poly-medicated.

In this regard, recent research conducted with crude natural extracts such as plants, sea organisms and mushrooms has shown their effectiveness as anti-inflammatory and antiviral agents through several mechanisms [15,16]. Edible mushrooms or yeasts have many nutritional and medicinal values to human health. As an example, *Hericium erinaceus* extract showed promising antimicrobial, antioxidant, and antiviral activity [17]. Yeasts such as *Saccharomyces cerevisiae* and *Saccharomyces boulardii* have proven *in vivo* their protective effects against bacterial translocation, their preservation of the gut barrier function and their regulation of immunity. In many cases, though, the beneficial immune modulation effects were seen when the administration was given prior to the challenge [18,19].

A nutritional supplement composed of a synergistic combination of yeast-based ingredients (ABB C1[®]) showed the ability to stimulate trained immunity in a randomized controlled trial on volunteers vaccinated against influenza or COVID-19 after a short supplementation period which started at the time of the vaccination [20]. ABB C1[®] is a unique combination of a β -1,3/1,6-glucan complex extracted from the cell wall of *Saccharomyces cerevisiae* through a gentle process that preserves its structure, and a consortium of postbiotic *Saccharomyces cerevisiae* fermented in the presence of selenium and zinc. ABB C1[®] represents a unique source of yeast β -glucan and highly bioavailable selenium and zinc.

Selenium is a potent antioxidant, enhances the function of cytotoxic effector cells, and is important for maintaining T-cell maturation, functions, and T-cell-dependent antibody production [21]. Recent review articles of selenium deficiency and viral infection show that lower serum selenium levels are associated with worse prognosis of infectious disease [22]. Nutritional intervention securing an adequate supply of selenium has been recommended for raising antiviral resistance [23]. In a similar way, zinc is a critical trace mineral for antiviral immunity. Results of five studies with 1506 participants included in a meta-analysis showed that zinc supplementation led to a significantly lower risk of mortality in COVID-19 patients when it was compared with non-supplemented controls [24]. On the other hand, β -glucan is a polysaccharide that is abundantly found in the cell wall of *S. cerevisiae* and primes the immune system to respond better to any viral infection [25]. Additionally, the use of oral β -glucan has been hypothesized to boost immune responses and abrogate symptoms in viral infection [26,27]. Therefore, it was considered of interest to assess the anti-inflammatory effect of ABB C1[®] on intestinal cells, on the preservation of the gut barrier integrity and on activity in stimulating phagocytosis of peripheral cells. Confirmation of the favourable effects of ABB C1[®] in these experimental studies may explain some of the mechanisms of action by which ABB C1[®] exerts its clinical benefits and would further support its use as a dietary supplement for improving the immune response to infectious diseases, and its use in preventing allergic processes.

2. Materials and Methods

2.1. Investigational Product

The investigation product (ABB C1[®], AB Biotek Human Nutrition & Health, Peterborough, UK) was composed of a synergistic combination of yeast-based ingredients: a β -1,3/1,6-glucan complex from *S. cerevisiae* (68.89%) and a consortium of heat-treated postbiotic *S. cerevisiae* rich in selenium and zinc (31.11%).

2.2. Anti-Inflammatory Effect of ABB C1[®] on Intestinal Cells/Epithelial Signalling Assay

The anti-inflammatory effect of ABB C1[®] on intestinal cells was studied by chemokine production by caco-2 cells in the presence and absence of a pro-inflammatory stimulus (adapted from [28]). Caco-2 cells were cultured to confluence in 96-well plates in culture medium (modified Eagle's medium MEM), supplemented with 20% (*v/v*) foetal bovine serum (FBS), 1% non-essential amino acids (NEAA), 1% Glutamax[™], 1% sodium pyruvate, with or without 1% penicillin-streptomycin and gentamicin (50 μ g/mL) (all obtained from Invitrogen, Breda, The Netherlands). At the start of the experiment, cells were washed once

with antibiotic-free culture medium. The monolayers were incubated with test components in triplicate for 1 h at 37 °C in antibiotic-free medium. Then, cells were further incubated for 24 h in the presence of the test components and 50 µg/mL gentamicin, with and without a mixture of recombinant tumour necrosis factor alpha (TNF-α) (10 ng/mL) and recombinant interferon (IFN-γ) (5 ng/mL) as a pro-inflammatory stimulus. Supernatants were collected 24 h after stimulation and stored at −20 °C. A Bio-Plex Multiplex Immunoassay System (Bio-Rad, Hercules, CA, USA) was used to measure IFN-γ-induced protein-10 (IP-10), and monocyte chemoattractant protein-1 (MCP-1) levels according to the manufacturer's instructions. IP-10 and MCP-1 levels were expressed as pg/mL. Both experiments were performed once in triplicate.

The metabolic activity of the cells for testing cytotoxicity of the test compounds was analysed by WST-1 assay (Roche), according to the manufacturers protocol, after collecting the culture supernatant of the epithelial signalling assay.

2.3. Gut Barrier Integrity Assay

Protection of epithelium disruption after a challenge: The effect of ABB C1[®] on gut barrier function upon a challenge was studied by transepithelial electric resistance (TEER) over a gut cell layer [29]. Caco-2 cells were cultured in MEM medium in the same conditions as in the previous experiment. Then, the cells were seeded (2×10^4 cells/cm²) on Transwell polycarbonate cell culture inserts with a mean pore size of 0.4 µm and a diameter of 0.33 cm², until full differentiation (± 1000 ohms [Ω]) (Greiner Bio-one, Alphen aan de Rijn, The Netherlands). As an indicative measure of barrier integrity, TEER was measured with an EVOM2 Epithelial Volt/Ohm Meter (World Precision Instruments). On the day of the experiment, the cells were washed and incubated for 1 h at 37 °C with antibiotic- and serum-free medium containing the test components. Subsequently, the wells were exposed to *Escherichia coli* ETEC H10407 infected at a multiplicity of infection (MOI) of 200 in the presence of the test components. TEER was measured before the start of the experiment ($t = -1$), 1 h after exposure to the test components before addition of the pathogens ($t = 0$), and 1 ($t = 1$), 2 ($t = 2$), 4 ($t = 4$), and 6 ($t = 6$) hours after exposure to the pathogens. The TEER values of the individual conditions after exposure to the pathogens were compared to their own TEER value at $t = 0$ and expressed as Δ TEER (Ω/cm²). A negative control (ETEC H10407 only) was included.

Spontaneous build-up of the epithelium: on the day of the experiment, the cells were washed and incubated for 1 h at 37 °C with antibiotic- and serum-free medium containing the test components. TEER was measured before the start of the experiment ($t = -1$) every 2 days for 22 days. The TEER values of the individual conditions were compared to their own TEER value at $t = 0$ and expressed as Δ TEER (Ω/cm²). A negative control without the study product was included. Both experiments were performed once in triplicate.

2.4. Stimulation of Phagocytosis of Peripheral Blood Monocytes and Leukocytes and Peritoneal Macrophages in Mice

In this experiment of phagocytosis of peripheral blood monocytes and leukocytes and peritoneal macrophages in mice, 10 BALB/c nude mice of both sexes and 8 weeks old were included in each study group. The products (control yeast β-1,3/1,6-glucan, control algae β-1,3-glucan, and ABB C1[®]) were given for 10 days by forced feeding. Eight samples of peripheral blood per mice were extracted (0.1 mL) from the mice fed with various doses of the products or PBS (negative control). Samples were incubated in vitro with 0.05 mL of 2-hydroxyethyl methacrylate particles (HEMA) (5×10^8 mL). The tubes were incubated at 37 °C for 60 min with intermittent shaking. Smears were stained with Wright's stain (Sigma-Aldrich, Merck KGaA, Darmstadt, Germany). The cells with three or more HEMA particles were considered positive. At least 300 cells were examined in each experiment. Results were standardized to reflect the β-glucan dosage received by the mice: 100% for the positive controls β-1-3/1,6 glucan from yeast and β-1,6-glucan from algae, and 68.89% for ABB C1[®].

The handling of the mice and all experimental procedures were conducted under regular conditions in accordance with the European Convention for the Care and Use of Laboratory Animals as approved by the Czech Animal Care and Use Committee. Last approval June 2021.

2.5. Statistical Analysis

Quantitative data are expressed as mean and standard deviation (\pm SD). The Student's *t* test (two-sided) or the one-way analysis of variance (ANOVA) with Dunnett's procedure was used for the comparison of data according to conditions of application. Statistical significance was set at $p < 0.05$.

3. Results

3.1. Anti-Inflammatory Effect on Intestinal Cells

ABB C1[®] cytotoxicity was discarded by a WST-1 assay before starting the anti-inflammatory effect on intestinal cells (data not shown). The anti-inflammatory effect evaluated in the presence and absence of a pro-inflammatory challenge (tumour necrosis factor alpha [TNF- α]/interferon gamma [IFN- γ]) showed statistically significant reductions in IP-10 and MCP-1 levels (Table 1).

Table 1. Anti-inflammatory effect of ABB C1[®] on intestinal cells/epithelial signalling assay. Mean differences in IP-10 and MCP-1 levels between negative control and ABB C1[®] and between negative control and ABB C1[®] after TNF- α /IFN- γ challenge. Both experiments were performed in triplicate.

Experimental Conditions	Mean \pm SD	ANOVA Test <i>p</i> -Value
IP-10 levels, pg/mL		
ABB C1 [®]	169.08 \pm 4.33	<i>p</i> < 0.0001
Control	225.87 \pm 15.39	
ABB C1 [®] with TNF- α /IFN- γ challenge	42,369.44 \pm 13,446.14	<i>p</i> = 0.0004
Control with TNF- α /IFN- γ challenge	62,363.65 \pm 4611.93	
MCP-1 levels, pg/mL		
ABB C1 [®]	2.87 (0.63)	<i>p</i> = 0.0104
Control	4.36 (0.53)	
ABB C1 [®] with TNF- α /IFN- γ challenge	19.50 (7.62)	<i>p</i> < 0.0001
Control with TNF- α /IFN- γ challenge	30.62 (2.80)	

SD: standard deviation, IP-10: IFN- γ -induced protein 10, MCP-1: monocyte chemoattractant protein 1. Significant differences ($p < 0.05$) are highlighted in bold.

3.2. Gut Barrier Integrity Assay

The capacity of ABB C1[®] to protect the gut epithelium from disruption caused by an infectious agent *Escherichia coli* ETEC H10407 was evaluated. Transepithelial electrical resistance (TEER) values were significantly higher for ABB C1[®] after 1 and 6 h of testing, with $p < 0.05$ and $p < 0.1$, respectively (Figure 1, left panel). The total area under the curve (AUC) showed a statistical trend towards a significant increase in the ABB C1[®] condition ($p < 0.1$). In addition, spontaneous build-up of the gut epithelium monolayer over 22 days was also greater in the ABB C1[®] condition as compared with a negative control (Figure 1, right panel). Numerical values are shown in Tables 2 and 3.




Figure 1. Gut barrier integrity assay in the presence of an infectious agent causing disruption of the gut epithelium. 1 h difference in the reduction of Δ TEER was statistically significant in favour of ABB C1[®] ($p < 0.05$). A trend towards statistical significance in favour of ABB C1[®] was found at 6 h difference in the reduction of Δ TEER and in the total negative AUC ($p < 0.1$) (left panel). The comparison of Δ TEER values over the course of 22 days indicates a higher spontaneous build-up of the epithelium monolayer for the ABB C1[®] condition versus a negative control, even if it did not reach statistical significance (right panel). Both experiments were performed once in triplicate.

Table 2. Results of gut barrier integrity over the course of 6 h.

Δ TEER Ω/cm^2	Experimental Condition			<i>t</i> -Test <i>p</i> -Value
	ABB C1 [®]	Control		
	Mean (SD)	Mean (SD)		
t = 0	0	0	-	
t = 1	3.33 (5.77)	-15.33 (7.51)	0.030	
t = 2	12.67 (6.66)	-9.33 (16.01)	0.126	
t = 4	-13.0 (11.14)	-19.00 (7.21)	0.484	
t = 6	-32.33 (15.57)	-59.33 (6.81)	0.078	
AUC				
Area of negative peaks	198.53 (57.38)	97.62 (53.56)	0.090	

AUC: area under the curve; SD: standard deviation; TEER: transepithelial electrical resistance, t: time (hours). Significant differences ($p < 0.05$) are highlighted in bold.

Table 3. Spontaneous build-up of gut epithelium monolayer for 22 days.

Δ TEER (Ω/cm^2)	Experimental Condition			<i>t</i> -Test <i>p</i> -Value
	ABB C1 [®]	Negative Control		
	Mean (SD)	Mean (SD)		
t = 4	0	0	-	
t = 6	104.33 (17.62)	109.0 (17.69)	0.940	
t = 8	223.0 (10.82)	226.33 (8.82)	0.497	
t = 10	246.67 (7.10)	250.67 (18.11)	0.464	
t = 12	254.0 (9.17)	253.33 (16.51)	0.780	
t = 14	259.33 (17.10)	246.33 (11.43)	0.455	
t = 16	247.67 (9.82)	231.0 (14.45)	0.169	
t = 18	244.33 (11.50)	235.50 (11.11)	0.315	
t = 20	240.67 (13.20)	231.33 (19.90)	0.530	
t = 22	246.67 (5.51)	228.0 (22.70)	0.141	

Table 3. Cont.

Δ TEER (Ω/cm^2)	Experimental Condition		
	ABB C1 [®]	Negative Control	<i>t</i> -Test
	Mean (SD)	Mean (SD)	<i>p</i> -Value
AUC			
Area of positive peaks	1913.00 (62.48)	1943.67 (48.00)	0.451

AUC: area under the curve; SD: standard deviation, TEER: transepithelial electrical resistance. t: time (days).

3.3. Stimulation of Phagocytosis of Peripheral Cells

In relation to stimulation of phagocytosis of peripheral blood monocytes and leukocytes and peritoneal macrophages cells *in vivo*, all samples showed activity; however, the highest activity was observed in the ABB C1[®] condition as compared with controls of algae β -1,3-glucan and yeast β -1,3/1,6 glucan (Figure 2 and Table 4).




Figure 2. Percentage of positive (phagocytosing) cells in the four experimental conditions. ABB C1[®] was significantly different from the negative control and from the yeast and algae β -glucan controls (***) $p < 0.001$. N = 10 mice per experimental condition.

Table 4. Stimulation of phagocytosis of peripheral cells in mice. N = 10 mice per experimental condition.

Experimental Condition	Percentage of Positive Cells, Mean \pm SD	<i>t</i> -Test <i>p</i> -Value vs. Control
ABB C1 [®]	71.37 (3.68)	$p < 0.001$
Control yeast β -1,3/1,6 glucan	52.75 (2.61)	$p < 0.001$
Control algae β -1,3-glucan	41.63 (2.44)	$p < 0.001$
Negative control	30.13 (1.40)	-

SD: standard deviation.

4. Discussion

In the two *in vitro* studies and in the experimental study in mice, the product based on a synergistic combination of β -glucans and selenium- and zinc-enriched *S. cerevisiae* (ABB C1[®]) showed significantly more favourable effects as compared with the control conditions regarding an anti-inflammatory effect, protection of the gut barrier from disruption, and stimulation of phagocytosis in peripheral blood monocytes, leukocytes and peritoneal macrophages.

The anti-inflammatory effect was shown by significantly lower levels of IP-10 and MCP-1 as compared to controls in both testing conditions, with and without TNF- α /INF- γ challenge mimicking inflammatory conditions.

Elevated IP-10 and MCP-1 levels in patients with infectious disease, and their possible usefulness as biomarkers of disease severity and therapeutic response, have been reported in different studies [30–37].

IP-10, also known as C–X–C motif chemokine 10 (CXCL10) or small-inducible cytokine B10, is a cytokine belonging to the CXC chemokine family. IP-10 binds with CXCR3 receptor, inducing chemotaxis, apoptosis, cell growth and angiostasis. Alterations in its expression levels have been associated with inflammatory diseases, including infectious diseases, immune dysregulation, and tumour development [36]. IP-10 is also recognized as a biomarker that predicts the severity of various infectious diseases. A study assessing 51 patients with pulmonary tuberculosis explored their evolution after 2 months of anti-tuberculosis therapy, showing that serum levels of IP-10 after treatment were associated with poor prognosis and long-term mortality [31].

MCP-1, also known as chemokine (CC-motif) ligand 2 (CCL2), has a vital role in the process of inflammation wherein it attracts or enhances the expression of other inflammatory factors/cells. By this mechanism of migration and infiltration of inflammatory cells and other cytokines at the site of inflammation, it is involved in the pathogenesis of numerous disease conditions either directly or indirectly [33]. Furthermore, high levels of MCP-1 have been reported to be useful for identifying poor outcomes in COVID-19 patients upon hospital admission [30,35,37].

For these reasons, the ability of ABB C1[®] to counteract these pro-inflammatory cytokines could be clinically relevant in the recovery and prognosis of infection.

Gut microbiome dysbiosis and gut barrier dysfunction in viral infection represent a source of bacteraemia, which may contribute to worsening outcomes [38]. Patients presenting poor outcomes are also those in which the immune system's hyperresponsiveness and a severe inflammatory condition (cytokine storm) are particularly evident and have been associated with impaired microbiota phenotype [39]. Alteration of gut microbiota increases the risk of microbial translocation and reflects disease severity and dysfunctional immune response in infection [40]. The results of our *in vitro* study of the protective effect of ABB C1[®] against disruption of the gut barrier and enhancement of spontaneous build-up of the gut epithelium monolayer support a plausible beneficial effect of dietary supplementation with ABB C1[®] in infectious diseases. Furthermore, several studies reviewed by Wesemann and Nagler explain the potential role of microbiome and barrier function in allergies, including but not limited to food allergies [41]. Based on its combined anti-inflammatory effect and preservation of gut barrier function, nutritional supplementation with ABB C1[®] may play a role that contributes to improving symptoms and reducing the severity of infections and allergies.

In the experimental study of stimulation of phagocytosis of peripheral cells in mice, two positive controls previously tested in the laboratory were included in the experiment: a β -1,3/1,6 glucan from yeast and a β -1,3-glucan from algae. The algae glucan had the lower effect, which is consistent with its chemical structure, comprising a linear carbohydrate chain with β -1,3 bonds [42]. Phagocytosis is known to play a crucial role in initiating the innate immune response against infection. Although phagocytic functions are performed through binding of pathogen-associated molecular patterns (PAMP) with their cell surface receptors on the phagocytes, leading to signal transduction and the release of inflammatory mediators, β -glucan-induced phagocytosis is mediated by various phagocytic receptors, mainly dectin-1 and complement receptors (CR3), and contributes to initiation of immune responses [43,44].

Future research to explore potential direct antiviral and antimicrobial effects could be of help to further support the benefits of supplementation with ABB C1[®] as an immune modulator in infectious disease.

5. Conclusions

Taken together, the findings of these three experimental studies show that ABB C1[®], which is a combination of yeast-based ingredients with a unique 1,3/1,6-glucan com-

plex and a consortium of postbiotic *S. cerevisiae* rich in selenium and zinc, exhibited anti-inflammatory properties, protected of the gut barrier, and stimulated phagocytosis. Given the safety and tolerability of the product shown in a previous randomized controlled trial in healthy volunteers after vaccination against influenza or COVID-19 [20], and considering the present findings, the use of dietary supplementation with ABB C1® in immunological challenges such infectious disease or allergic episodes may be useful to ameliorate symptoms and improve prognoses in clinical practice.

Author Contributions: Conceptualization, M.T., J.C. and C.d.L.; methodology, M.T., J.C. and V.V.; software, M.T.; validation, M.T., J.C. and C.d.L.; formal analysis, M.T.; investigation, M.T., J.C., V.V. and C.d.L.; resources, C.d.L.; data curation, M.T.; writing—original draft preparation, M.T.; writing—review and editing, M.T., J.C., V.V. and C.d.L.; visualization, C.d.L. supervision, C.d.L.; project administration, M.T.; funding acquisition, C.d.L. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The animal study protocol was approved by the Czech Animal Care and Use Committee.

Informed Consent Statement: Not applicable.

Data Availability Statement: Study data are available from the authors upon request.

Acknowledgments: The authors thank Marta Pulido for editing the manuscript and editorial assistance.

Conflicts of Interest: M.T., J.C. and C.d.L. are full-time employees of AB Biotek Human Nutrition and Health.

References

1. Dinarello, C.A. Proinflammatory cytokines. *Chest* **2000**, *118*, 503–508. [[CrossRef](#)] [[PubMed](#)]
2. Arango Duque, G.; Descoteaux, A. Macrophage cytokines: Involvement in immunity and infectious diseases. *Front. Immunol.* **2014**, *5*, 491. [[CrossRef](#)] [[PubMed](#)]
3. Stow, J.L.; Murray, R.Z. Intracellular trafficking and secretion of inflammatory cytokines. *Cytokine Growth Factor Rev.* **2013**, *24*, 227–239. [[CrossRef](#)]
4. Geuking, M.B.; Köller, Y.; Rupp, S.; McCoy, K.D. The interplay between the gut microbiota and the immune system. *Gut Microbes* **2014**, *5*, 411–418. [[CrossRef](#)]
5. Hosseini, A.; Hashemi, V.; Shomali, N.; Asghari, F.; Gharibi, T.; Akbari, M.; Gholizadeh, S.; Jafari, A. Innate and adaptive immune responses against coronavirus. *Biomed. Pharmacother.* **2020**, *132*, 110859. [[CrossRef](#)]
6. Lotfi, R.; Kalmarzi, R.N.; Roghani, S.A. A review on the immune responses against novel emerging coronavirus (SARS-CoV-2). *Immunol. Res.* **2021**, *69*, 213–224. [[CrossRef](#)] [[PubMed](#)]
7. Lee, S.; Channappanavar, R.; Kanneganti, T.D. Coronaviruses: Innate immunity, inflammasome activation, inflammatory cell death, and cytokines. *Trends Immunol.* **2020**, *41*, 1083–1099. [[CrossRef](#)] [[PubMed](#)]
8. Ragusa, F.; Fallahi, P. IP-10 in occupational asthma: Review of the literature and case-control study. *Clin. Ter.* **2017**, *168*, e151–e157. [[CrossRef](#)]
9. Di Bari, F. Atopic dermatitis and alpha-chemokines. *Clin. Ter.* **2015**, *166*, e182–e187. [[CrossRef](#)] [[PubMed](#)]
10. Holla, L.I.; Mrazek, F.; Petrek, M. MCP-1 and CCR2 gene polymorphisms in Czech patients with allergic disorders. *Int. J. Immunogenet.* **2009**, *36*, 69–72. [[CrossRef](#)]
11. Mai, W.; Lu, D.; Liu, X.; Chen, L. MCP-1 produced by keratinocytes is associated with leucocyte recruitment during elicitation of nickel-induced occupational allergic contact dermatitis. *Toxicol. Ind. Health* **2018**, *34*, 36–43. [[CrossRef](#)]
12. Groschwitz, K.R.; Hogan, S.-P. Intestinal barrier function: Molecular regulation and disease pathogenesis. *J. Allergy Clin. Immunol.* **2009**, *124*, 3–20. [[CrossRef](#)]
13. Hamulka, J.; Jeruszka-Bielak, M.; Górnicka, M.; Drywień, M.E.; Zielinska-Pukos, M.A. Dietary supplements during COVID-19 outbreak. Results of Google Trends Analysis Supported by PLifeCOVID-19 Online Studies. *Nutrients* **2020**, *13*, 54. [[CrossRef](#)]
14. Costagliola, G.; Spada, E.; Comberiati, P.; Peroni, D.G. Could nutritional supplements act as therapeutic adjuvants in COVID-19? *Ital. J. Pediatr.* **2021**, *47*, 32. [[CrossRef](#)]
15. Suleiman, W.; Helal, E. Chemical constituents and potential pleiotropic activities of *Foeniculum vulgare* (Fennel) ethanolic extract; in vitro approach. *Egypt. J. Chem.* **2022**, *65*, 617–626. [[CrossRef](#)]

16. El-Naggar, H.A.; Bashar, M.A.E.; Rady, I.; El-Wetidy, M.S.; Suleiman, W.B.; Al-Otibi, F.O.; Al-Rashed, S.A.; Abd El-Maoula, L.M.; Salem, E.-S.S.; Attia, E.M.H.; et al. Two Red Sea Sponge Extracts (*Negombata magnifica* and *Callyspongia siphonella*) Induced Anticancer and Antimicrobial Activity. *Appl. Sci.* **2022**, *12*, 1400. [[CrossRef](#)]
17. Suleiman, W.B.; Shehata, R.M.; Younis, A.M. In vitro assessment of multipotential therapeutic importance of *Hericium erinaceus* mushroom extracts using different solvents. *Bioresour. Bioprocess.* **2022**, *9*, 99. [[CrossRef](#)]
18. Generoso, S.V.; Viana, M.; Santos, R.; Martins, F.S.; Machado, J.A.; Arantes, R.M.; Nicoli, J.R.; Correia, M.I.; Cardoso, V.N. *Saccharomyces cerevisiae* strain UFMG 905 protects against bacterial translocation, preserves gut barrier integrity and stimulates the immune system in a murine intestinal obstruction model. *Arch. Microbiol.* **2010**, *192*, 477–484. [[CrossRef](#)] [[PubMed](#)]
19. Generoso, S.V.; Viana, M.; Santos, R.; Martins, F.S.; Machado, J.A.; Arantes, R.M.; Nicoli, J.R.; Correia, M.I.; Cardoso, V.N. Protection against increased intestinal permeability and bacterial translocation induced by intestinal obstruction in mice treated with viable and heat-killed *Saccharomyces boulardii*. *Eur. J. Nutr.* **2011**, *50*, 261–269. [[CrossRef](#)] [[PubMed](#)]
20. Rodriguez, J.A.M.; Bifano, M.; Roca Goma, E.; Plasencia, C.M.; Torralba, A.O.; Font, M.S.; Millán, P.R. Effect and tolerability of a nutritional supplement based on a synergistic combination of β -glucans and selenium- and zinc-enriched *Saccharomyces cerevisiae* (ABB C1®) in volunteers receiving the influenza or the COVID-19 vaccine: A randomized, double-blind, placebo-controlled study. *Nutrients* **2021**, *13*, 4347. [[CrossRef](#)] [[PubMed](#)]
21. Bae, M.; Kim, H. Mini-Review on the roles of vitamin C, vitamin D, and selenium in the immune system against COVID-19. *Molecules* **2020**, *25*, 5346. [[CrossRef](#)] [[PubMed](#)]
22. Fakhrolmobasheri, M.; Mazaheri-Tehrani, S.; Kieliszek, M.; Zeinalian, M.; Abbasi, M.; Karimi, F.; Mozafari, A.M. COVID-19 and selenium deficiency: A systematic review. *Biol. Trace Elem. Res.* **2022**, *200*, 3945–3956. [[CrossRef](#)]
23. Sales Martinez, S.; Huang, Y.; Acuna, L.; Laverde, E.; Trujillo, D.; Barbieri, M.A.; Tamargo, J.; Campa, A.; Baum, M. Role of Selenium in Viral Infections with a Major Focus on SARS-CoV-2. *Int. J. Mol. Sci.* **2022**, *23*, 280. [[CrossRef](#)]
24. Tabatabaeizadeh, S.A. Zinc supplementation and COVID-19 mortality: A meta-analysis. *Eur. J. Med. Res.* **2022**, *27*, 70. [[CrossRef](#)]
25. Jawhara, S. How to boost the immune defence prior to respiratory virus infections with the special focus on coronavirus infections. *Gut Pathog.* **2020**, *12*, 47. [[CrossRef](#)] [[PubMed](#)]
26. Geller, A.; Yan, J. Could the induction of trained immunity by β -glucan serve as a defense against COVID-19? *Front. Immunol.* **2020**, *11*, 1782. [[CrossRef](#)]
27. Bashir, K.M.I.; Choi, J.S. Clinical and Physiological Perspectives of β -Glucans: The Past, Present, and Future. *Int. J. Mol. Sci.* **2017**, *18*, 1906. [[CrossRef](#)] [[PubMed](#)]
28. Van De Walle, J.; Hendrickx, A.; Romier, B.; Larondelle, Y.; Schneider, Y.-J. Inflammatory parameters in Caco-2 cells: Effect of stimuli nature, concentration, combination and cell differentiation. *Toxicol. Vitro.* **2010**, *24*, 1441–1449. [[CrossRef](#)]
29. Chen, S.; Einspanier, R.; Schoen, J. Transepithelial electrical resistance (TEER): A functional parameter to monitor the quality of oviduct epithelial cells cultured on filter supports. *Histochem. Cell Biol.* **2015**, *144*, 509–515. [[CrossRef](#)]
30. Chen, Y.; Wang, J.; Liu, C.; Su, L.; Zhang, D.; Fan, J.; Yang, Y.; Xiao, M.; Xie, J.; Xu, Y.; et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. *Mol. Med.* **2020**, *26*, 97. [[CrossRef](#)]
31. Chen, Y.-C.; Chin, C.-h.; Liu, S.-F.; Wu, C.-C.; Tsen, C.-C.; Wang, Y.-H.; Chao, T.-Y.; Lie, C.-H.; Chen, C.-j.; Wang, C.-C.; et al. Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. *Dis. Markers* **2011**, *31*, 938794. [[CrossRef](#)]
32. Pons, M.J.; Ymaña, B.; Mayanga-Herrera, A.; Sáenz, Y.; Alvarez-Erviti, L.; Tapia-Rojas, S.; Gamarra, R.; Blanco, A.B.; Moncunill, G.; Ugarte-Gil, M.F. Cytokine profiles associated with worse prognosis in a hospitalized Peruvian COVID-19 cohort. *Front. Immunol.* **2021**, *12*, 700921. [[CrossRef](#)] [[PubMed](#)]
33. Singh, S.; Anshita, D.; Ravichandiran, V. MCP-1: Function, regulation, and involvement in disease. *Int. Immunopharmacol.* **2021**, *101*, 107598. [[CrossRef](#)] [[PubMed](#)]
34. Zanza, C.; Romenskaya, T.; Manetti, A.C.; Franceschi, F.; La Russa, R.; Bertozzi, G.; Maiese, A.; Savioli, G.; Volonnino, G.; Longhitano, Y. Cytokine Storm in COVID-19: Immunopathogenesis and therapy. *Medicina* **2022**, *58*, 144. [[CrossRef](#)] [[PubMed](#)]
35. Kumboyono, K.; Chomsoy, I.N.; Iskandar, A.; Aryati, A.; Parwati, I.; Wihastuti, T.A. The potential predictive role of tumour necrosis factor- α , interleukin-1 β , and monocyte chemoattractant protein-1 for COVID-19 patients survival. *Infect. Drug Resist.* **2022**, *15*, 821–829. [[CrossRef](#)]
36. Liu, M.; Guo, S.; Hibbert, J.M.; Jain, V.; Singh, N.; Wilson, N.O.; Stiles, J.K. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. *Cytokine Growth Factor Rev.* **2011**, *22*, 121–130. [[CrossRef](#)]
37. Lu, Q.; Zhu, Z.; Tan, C.; Zhou, H.; Hu, Y.; Shen, G.; Zhu, P.; Yang, G.; Xie, X. Changes of serum IL-10, IL-1 β , IL-6, MCP-1, TNF- α , IP-10 and IL-4 in COVID-19 patients. *Int. J. Clin. Pract.* **2021**, *75*, e14462. [[CrossRef](#)]
38. Prasad, R.; Patton, M.J.; Floyd, J.L.; Vieira, C.P.; Fortmann, S.; DuPont, M.; Harbour, A.; Jeremy, C.S.; Wright, J.; Lamendella, R.; et al. Plasma microbiome in COVID-19 subjects: An indicator of gut barrier defects and dysbiosis. *bioRxiv* **2021**. [[CrossRef](#)]
39. Ferreira, C.; Viana, S.D.; Reis, F. Gut microbiota dysbiosis-immune hyperresponse-inflammation triad in coronavirus disease 2019 (COVID-19): Impact of pharmacological and nutraceutical approaches. *Microorganisms* **2020**, *8*, 1514. [[CrossRef](#)]
40. Yeoh, Y.K.; Zuo, T.; Lui, G.C.; Zhang, F.; Liu, Q.; Li, A.Y.; Chung, A.C.; Cheung, C.P.; Tso, E.Y.; Fung, K.S.; et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. *Gut* **2021**, *70*, 698–706. [[CrossRef](#)]
41. Wesemann, D.R.; Nagler, C.R. The Microbiome, Timing, and Barrier Function in the Context of Allergic Disease. *Immunity* **2016**, *44*, 728–738. [[CrossRef](#)] [[PubMed](#)]

42. Raa, J. Immune modulation by non-digestible and non-absorbable beta-1,3/1,6-glucan. *Microb. Ecol. Health Dis.* **2015**, *26*, 27824. [[CrossRef](#)] [[PubMed](#)]
43. Goodridge, H.S.; Wolf, A.J.; Underhill, D.M. Beta-glucan recognition by the innate immune system. *Immunol. Rev.* **2009**, *230*, 38–50. [[CrossRef](#)] [[PubMed](#)]
44. Zhang, Y.; Liu, X.; Zhao, J.; Wang, J.; Song, Q.; Zhao, C. The phagocytic receptors of β -glucan. *Int. J. Biol. Macromol.* **2022**, *205*, 430–441. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.